Alnylam Named in Complaint Over RNAi Patents

A week after settling litigation related to the patents on gene-silencing treatments, Alnylam Pharmaceuticals and others have found themselves in another legal battle over the Tuschl patents related to RNA-interference treatments. This time the University of Utah has named Cambridge, MA-based Alnylam (NASDAQ:ALNY), Max Planck, the Whitehead Institute for Biomedical Research, MIT, and the University of Massachusetts in a civil complaint filed in federal court in Massachusetts on Tuesday, Alnylam said in a regulatory filing.

Trending on Xconomy